Literature DB >> 3943608

Heparin and the solubilization of asymmetric acetylcholinesterase.

A Barat, E Escudero, G Ramírez.   

Abstract

Heparin solubilizes asymmetric acetylcholinesterase, from chick skeletal muscle and retina, as a 24 S complex which is quantitatively converted to conventional asymmetric molecular forms of the enzyme (A12 and A8, either class I or class II) upon exposure to high salt. The simultaneous presence of salt and heparin in the homogenization medium selectively prevents, however, the release of class II A-forms in both muscle and retina. Heparin may generally act by displacing native proteoglycans involved in the attachment of the enzyme tail to the extracellular matrix, or its neural equivalent, being in turn removed by salt to yield typical asymmetric enzyme forms. Heparin would also appear to displace some other molecules specifically involved in the EDTA-sensitive attachment of class II tailed forms, this effect being antagonized by salt.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943608     DOI: 10.1016/0014-5793(86)80162-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Two types of asymmetric acetylcholinesterase in chick hindlimb muscle: developmental profiles, in vivo and in cell culture, and recovery after inactivation.

Authors:  X Busquets; J Pérez-Tur; P Rosario; G Ramírez
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

2.  Stabilization of collagen-tailed acetylcholinesterase in muscle cells through extracellular anchorage by transglutaminase-catalyzed cross-linking.

Authors:  D Hand; D Dias; L W Haynes
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

3.  Phosphatidylinositol is involved in the attachment of tailed asymmetric acetylcholinesterase to neuronal membranes.

Authors:  M Verdière-Sahuqué; L Garcia; P A Dreyfus; D Goudou; M Nicolet; F Rieger
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.